Efficacy of combined antibacterial-prebiotic therapy in combination with D-mannose in women with uncomplicated lower urinary tract  infection

Kuzmenko, A V; Kuzmenko, V V; Gyaurgiev, T A

doi:10.18565/urology.2019.6.38-43

Cited by 7 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Несмотря на то, что механизм лечебного действия D-маннозы у больных рецидивирующими ИНМП хорошо изучен, клинических исследований в данном направлении относительно немного [21][22][23][24]. В исследовании B. Kranjčec et al [21] показано, что назначение 2 г D-маннозы в сутки в течение 6 мес.…”

Section: Discussionunclassified

“…Начало было положено в 1979 г., когда израильские микробиологи под руководством профессора M. Аронсона установили, что при высокой концентрации D-маннозы в моче частота возникновения ИНМП снижается на 67% [20]. Полученные впоследствии экспериментальные и клинические данные подтвердили наличие антиадгезивного эффекта D-маннозы в отношении E. coli и других уропатогенов [21][22][23][24].…”

Section: Introductionunclassified

See 1 more Smart Citation

Non-antibiotic prevention of postcoital cystitis in women

Kuzmin¹,

Slesarevskaya²,

Аль-Шукри³

2021

Russian Journal of Woman and Child Health

View full text Add to dashboard Cite

Background: postcoital cystitis ranks first among recurrent infections of the lower urinary tract in young women. Their prevention is an important medical social issue. Prescription of antimicrobials for these infections increases antibacterial resistance of urinary tract pathogens, thereby requiring the search for alternative preventive strategies for postcoital cystitis. Aim: to assess the effectiveness of diet correction using biologically active food supplement (BAFS) Ecocystin® containing D-mannose and inulin to prevent coitus-related infections of the lower urinary tract (postcoital cystitis) in women. Patients and Methods: 40 sexually active women aged 18–45 (the mean age 31.9±8.8 years) with recurrent coitus-related infections of the lower urinary tract were enrolled. Women were divided into two groups, i.e., the study group (n=22) and the control group (n=18). Study group women received postcoital preventive treatment for the lower urinary tract infections (one sachet of BAFS Ecocystin® containing 1.5 g of mannose and 1.5 g of inulin no later than 2 hours after sexual intercourse and then another 12 hours later). Control group women received no preventive treatment. The primary indicator of the efficacy of postcoital prophylaxis was the rate of recurrent infections of the lower urinary tract. The additional indicator was the severity of clinical presentations assessed by the Acute Cystitis Symptom Score (ACSS) questionnaire. Follow-up was six months. Results: the rate of recurrent infections of the lower urinary tract was significantly lower in the study group compared to the control group. Recurrences were reported in 27.3% in the study group and 77.8% in the control group over months 1–3 (χ2=10.01, p=0.002) and 13.6% and 72.2%, respectively, over months 4–6 (χ2=14.16, p<0.001). The chances for cystitis exacerbation during the first and the second trimester of the follow-up were 2.9- and 5.3-times lower in the study group compared to the control group. During the first trimester of the follow-up, the recurrence rate was 0.45±0.86 per one woman of the study group and 1.55±1.10 per one of the control group (t=3.6, p<0.001). During the second trimester of the follow-up, the recurrence rate was 0.18±0.50 and 1.50±1.20 (t=4.7, p<0.001), respectively. Women who received BAFS Ecocystin® but developed postcoital cystitis reported much lower symptom severity than the control group. As a result, the study group’s quality of life was significantly higher than the control group’s. Conclusions: BAFS Ecocystin® is a highly effective and well-tolerated preventive tool for postcoital cystitis in women and a pathogenetically reasonable alternative for antibiotics. KEYWORDS: postcoital cystitis, infections of the lower urinary tract, recurrent cystitis, Ecocystin, D-mannose, inulin, non-antibiotic prophylaxis. FOR CITATION: Kuz’min I.V., Slesarevskaya M.N., Al’-Shukri S.Kh. Non-antibiotic prevention of postcoital cystitis in women. Russian Journal of Woman and Child Health. 2021;4(3):209–217 (in Russ.). DOI: 10.32364/2618-8430-2021-4-3-209-217.

show abstract

Section: Discussionunclassified

Section: Introductionunclassified

Non-antibiotic prevention of postcoital cystitis in women

Kuzmin¹,

Slesarevskaya²,

Аль-Шукри³

2021

Russian Journal of Woman and Child Health

View full text Add to dashboard Cite

show abstract

“…The results of another study indicated that D-mannose efficiently blocked the adhesive properties of all type 1 fimbriae-positive isolates of E. coli in low concentration, but did not show any bacteriostatic effects [102]. The results of another study demonstrated that antibiotic therapy in combination with long-term enrichment of the diet with D-mannose leads to prolongation of the inter-relapse period of uncomplicated UTI [97].…”

Section: Other Agentsmentioning

confidence: 98%

“…So, the use of the sugar or its analogs can help to block the adhesion of E. coli to the bladder epithelium. The efficacy of these sugars in controlling UTI has been studied previously [96][97][98].…”

Section: Other Agentsmentioning

confidence: 99%

Deep insights into urinary tract infections and effective natural remedies

et al. 2021

View full text Add to dashboard Cite

Background Urinary tract infection (UTI) is a common occurrence in females, during pregnancy, and in peri- and postmenopausal women. UTIs are associated with significant morbidity and mortality, and they affect the quality of life of the affected patients. Antibiotic therapy is an effective approach and reduces the duration of symptoms. Development of resistance, adverse effects of antibiotics, and other associated problems lead to establishing the research framework to find out the alternative approaches in controlling UTIs. Natural approaches have been extensively used for the management of various diseases to improve symptoms and also improve general health. Main body Different databases were employed to identify studies reporting on natural options including herbal medicines, vitamins, trace elementals, sugars, and probiotics without time limitations. Conclusion Herbal medicines can be effective at the first sign of the infection and also for short-term prophylaxis. Using vitamins, trace elementals, and/or sugars is an effective approach in preventing UTIs, and a combination of them with other antibacterial agents shows positive results. Probiotics have great potential for the threat of antibiotic over-usage and the prevalence of antibiotic-resistant microorganisms. This study may be of use in developing the efficient formulation of treatment of UTI.

show abstract

“…This finding is supported by recent smaller studies. [15][16][17][18] Although there are indicators of efficacy from small underpowered trials, the only adequately powered study to date 15 was not placebo controlled and found an unexpectedly high RUTI incidence in the control arm. Furthermore, a microbiologically confirmed UTI was a requirement for entry to the study, and participants were withdrawn once they developed a UTI on treatment.…”

Section: Strengths and Limitations Of This Studymentioning

confidence: 99%

D-MannosE to prevent Recurrent urinary tract InfecTions (MERIT): protocol for a randomised controlled trial

et al. 2021

View full text Add to dashboard Cite

IntroductionRecurrent urinary tract infections (RUTIs) have a significant negative impact on quality of life and healthcare costs. To date, daily prophylactic antibiotics are the only treatment which have been shown to help prevent RUTIs. D-mannose is a type of sugar which is believed to inhibit bacterial adherence to uroepithelial cells, and is already being used by some women in an attempt to prevent RUTIs. There is currently insufficient rigorous evidence on which to base decisions about its use. The D-mannose to prevent recurrent urinary tract infections (MERIT) study will evaluate whether D-mannose is clinically and cost-effective in reducing frequency of infection and symptom burden for women presenting to UK primary care with RUTI.Methods and analysisMERIT will be a two-arm, individually randomised, double blind placebo controlled, pragmatic trial. Participants will be randomised to take D-mannose powder or placebo powder daily for 6 months. The primary outcome will be the number of medical attendances attributable to symptoms of RUTI. With 508 participants we will have 90% power to detect a 50% reduction in the chance of a further clinically suspected UTI, assuming 20% lost to follow-up. Secondary outcomes will include: number of days of moderately bad symptoms of UTI; time to next consultation; number of clinically suspected UTIs; number of microbiologically proven UTIs; number of antibiotic courses for UTI; quality of life and healthcare utilisation related to UTI. A within trial economic evaluation will be conducted to examine cost-effectiveness of D-mannose in comparison with placebo. A nested qualitative study will explore participants’ experiences and perceptions of recruitment to, and participation in a study requiring a daily treatment.Ethics and disseminationEthical approval has been obtained from South West-Central Bristol Research Ethics Committee. Publication of the MERIT study is anticipated to occur in 2021.Trial registration numberISRCTN 13283516.

show abstract

Efficacy of combined antibacterial-prebiotic therapy in combination with D-mannose in women with uncomplicated lower urinary tract infection

Cited by 7 publications

References 0 publications

Non-antibiotic prevention of postcoital cystitis in women

Non-antibiotic prevention of postcoital cystitis in women

Deep insights into urinary tract infections and effective natural remedies

D-MannosE to prevent Recurrent urinary tract InfecTions (MERIT): protocol for a randomised controlled trial

Contact Info

Product

Resources

About